18^th International Conference on Alzheimer's disease and Dementia September 19-20, 2024 Paris, France

Session Name: Neurology

Track: 1 Advances in Alzheimer's Disease Research

Track: 2 Neuroimaging in Dementia Diagnosis

Track: 3 Updates in Alzheimer's Disease Treatment

Track: 4 Genetics and Biomarkers in Dementia

Session Name: Psychiatry

Track: 5 Behavioral and Psychological Symptoms of Dementia (BPSD)

Track: 6 Management of Neuropsychiatric Symptoms in Alzheimer's Disease

Track: 7 Psychosocial Interventions for Dementia Caregivers

Track: 8 Depression and Anxiety in Alzheimer's Disease

Session Name: Geriatrics

Track: 9 Geriatric Syndromes in Dementia

Track: 10 Multidisciplinary Approaches to Dementia Care

Track: 11 Palliative Care and End-of-Life Issues in Dementia

Track: 12 Aging and Cognitive Health

Session Name: Mental Health 

Track: 13 Cognitive Rehabilitation Strategies for Dementia

Track: 14 Addressing Stigma and Dementia Awareness

Track: 15 Dementia and Caregiver Support Services

Track: 16 Legal and Ethical Considerations in Dementia Care

Session Name: Research

Track: 17 Clinical Trials and Drug Development in Alzheimer's Disease

Track: 18 Translational Research in Dementia

Track: 19 Epidemiology and Risk Factors for Dementia

Track: 20 Technology and Innovation in Dementia Care

Session Name: Research

Track: 21 Empowering and Supporting Family Caregivers

Track: 22 Respite Care and Self-Care for Caregivers

Track: 23 Community Resources and Support for Dementia Caregivers

Track: 24 Long-Term Care Planning and Decision-Making

Neurologists: Medical doctors who specialize in the diagnosis, treatment, and management of neurological disorders, including Alzheimer's disease and dementia.

Researchers and Scientists: Professionals engaged in cutting-edge research related to neurology, Alzheimer's disease, dementia, and other cognitive disorders.

Clinicians: Healthcare professionals involved in the direct care and treatment of individuals with Alzheimer's disease and dementia.

Geriatricians: Doctors specializing in the care of elderly patients, including the diagnosis and management of cognitive disorders.

Psychiatrists and Psychologists: Professionals with expertise in mental health and cognitive functions, often involved in the assessment and treatment of dementia-related behavioral symptoms.

Neuroscientists: Researchers focused on understanding the brain's structure, function, and mechanisms underlying cognitive decline.

Nursing Professionals: Nurses specialized in geriatric care, dementia care, and related fields.

Pharmacologists: Experts in studying the effects of drugs and medications on neurological conditions, including Alzheimer's disease.

Healthcare Administrators: Professionals involved in managing healthcare facilities, policies, and resources related to neurology and dementia care.

Caregivers and Family Members: Individuals who provide care and support to patients with Alzheimer's disease and dementia, seeking information and resources to better understand and manage these conditions.

Pharmaceutical Industry Representatives: Professionals from pharmaceutical companies engaged in the development of medications and treatments for Alzheimer's disease and related disorders.

Academics and Educators: Individuals involved in teaching and educating others about neurology, Alzheimer's disease, and dementia.

Government and Policy Makers: Officials involved in shaping healthcare policies and regulations related to neurological disorders and dementia care.

Non-profit Organizations and Advocates: Representatives from organizations dedicated to raising awareness, providing support, and advocating for individuals with Alzheimer's disease and their families.

Students and Trainees: Medical students, graduate students, and trainees interested in neurology and related fields.

Alzheimer's Diagnostics Market:

Alzheimer's Diagnostics (AD) Market by Diagnostic  Type (Brain Imaging [Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and Others], Genetic Testing, Blood Testing and Others ), according to end users (hospitals and clinics, diagnostic centers and others) and geographically, it is expected to reach a decent CAGR forecast by 2028 due to the increasing  incidence of brain injury, dementia and Alzheimer's disease and other diseases the growing burden of the world population.

The global market for Alzheimer's Diagnostics (AD) is projected to grow at a CAGR of 10.97% during the forecast period 2023 to 2028. The Alzheimer's disease (AD) Diagnostics Market is witnessing bullish growth of the market driven by factors such as the regulatory approvals for Alzheimer's disease (AD) diagnosis in the world. In addition, the increasing incidence of head trauma due to accidents, work injuries and the like, and the increasing geriatric population will increase the incidence of Alzheimer's disease, thereby increasing the demand for Alzheimer's disease diagnostic equipment worldwide. Furthermore, increasing research and development of new biomarkers, presence of key market players, increase in product launches and approvals, etc. will create a need for Alzheimer's disease diagnosis in the coming years. Therefore, the Alzheimer's disease (AD) Diagnostics Market is anticipated to grow at a substantial CAGR during the forecast period 2023 to 2028.

Dynamics of Alzheimer's disease (AD) Diagnostics Market:

One of the key aspects driving the disease market is the growing prevalence of dementia around the world. Alzheimer's disease is a form of dementia that affects memory, thinking, and behavior. Therefore, the increasing prevalence of dementia will increase the incidence of Alzheimer's disease and ultimately increase the need for related diagnostic equipment. For example, according to the World Health Organization (WHO), an estimated 55 million people worldwide will be diagnosed with dementia in 2022, more than 60% of whom live in low- and middle-income countries. In addition, as the proportion of older people in the population increases in almost all countries, this number is projected to increase to 78 million in 2030 and 139 million in 2050.

In addition, increasing regulatory approval of Alzheimer's disease (AD) diagnostics is expected to be another important driver for the Alzheimer's disease (AD) diagnostics market. Different product launches in this field are different markets driving the market growth.

For example, in May 2022, Fujirebio Diagnostics, a global leader in high quality in vitro diagnostics (IVD), received the green light from the US Food and Drug Administration (FDA) for its Lumipulse G β-Amyloid Ratio (1). -42/1-40), which is aimed at people with cognitive impairments aged 55 and over. The test has also been cited as a revolutionary device for faster verification of assets that meet an unmet need. Additionally, in February 2022, Diadem, a pure-play diagnostics company, received CE-IVD Mark for its non-invasive, plasma-based predictive blood test AlzoSure Predict, used for early detection of Alzheimer's disease (AD). Thus, the growing number of regulatory approvals for the diagnosis of Alzheimer's disease (AD) underscores the need for diagnostic tests due to the increasing prevalence of the disease, which is driving the overall market for Alzheimer's disease diagnosis. Period 2023-2028. Therefore, the factors listed above together will drive the overall Alzheimer's disease (AD) diagnosis market during the forecast period 2023-2028.  However, the high cost of brain imaging, stigma and lack of awareness for the diagnosis of the Alzheimer's disease and other factors could jeopardize the development of the Alzheimer's disease (AD) diagnosis market.

Alzheimer's disease (AD) diagnostics market has been negatively impacted during the COVID-19 pandemic due to the reduction in the number of diagnostic tests due to the massive spread of the COVID-19 infection in the world. Also, in order to contain the spread of the infection, governments around the world have enacted strict containment rules, resulting in a shortage of supply chains, raw materials and other resources in the market, leading to a reduction in the production of all medical devices. In addition, patients and doctors have postponed many scheduled surgeries, diagnostic tests, and visits to laboratories and other healthcare facilities to stop the spread of infection, reducing visits to hospitals and clinics for diagnosis and treatment. However, with the easing of quarantine restrictions and a return to normalcy in the economic landscape, the development of a COVID-19 vaccine has ushered in a process of economic recovery that has started the process of resuming regular health services in. B. Regular outpatient visits for treatment and diagnosis in hospitals, clinics and laboratories, which increases the demand for products in the Alzheimer's disease (AD) diagnostic equipment market.

Alzheimer’s Disease (AD) Diagnostic Market Segment Analysis:

Alzheimer's Diagnostics (AD) Market by Diagnostic Type (Brain Imaging [Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) and Others], Genetic Testing, Blood Testing and Others), End User (Hospitals). And clinics, diagnostic centers and more) and geography (North America, Europe, Asia Pacific and rest of the world). In the diagnostic segment of the Alzheimer's Diagnostics (AD) market, the Computed Tomography (CT) segment is expected to account for a majority of revenue in 2021. This is mainly due to the great advantages of computed tomography (CT). . For example, CT scans are used to detect the loss of brain mass associated with Alzheimer's disease (AD) and provide a detailed look inside the brain. It also helps to collect more images of the brain area from different angles. In addition, the study helps distinguish Alzheimer's disease (AD) from other types of dementia such as vascular dementia, mixed dementia and others. In addition, the increasing use of CT scans for brain imaging is also increasing the market demand for Alzheimer's disease (AD) diagnosis. For example, in May 2021, Koninklijke Philips N.V., a global leader in medical technology, announced the launch of its Spectral Computed Tomography (CT) 7500 system, which is based on a breast detector. The system provides high-quality spectral images for each patient, including head and other scans. Therefore, given the benefits and applications associated with the CT segment and the increase in product launches, this category is expected to witness significant growth, ultimately contributing to the overall growth of the global Alzheimer's Diagnostics (MA) market over the forecast period will contribute.

North America is expected to dominate the overall Alzheimer's diagnostics market:

Across all regions, North America is expected to dominate the global medical device testing services in 2021 and will continue to do so during the forecast period 2023 to 2028 This is due to the growing incidence of traumatic brain injuries, increasing geriatric population, increasing product launch and approvals in the region, presence of key market players in the region, and other factors driving the demand for Alzheimer's disease (AD) diagnoses in the region region will increase. Specific forecast period. For example, according to the latest 2021 data from the American Society of Biochemistry and Molecular Biology, one brain injury occurs every nine seconds in the United States, resulting in more than 3.5 million accidents annually.Also, according to the above source and statistics, approximately 2.8 million people suffer traumatic brain injury (TBI) in the United States each year, of which 2.80,000 are hospitalized. As a result, more and more cases of head injuries, such as B. traumatic brain injury (TBI), associated with a high risk of developing Alzheimer's disease.

In addition, the increasing incidence of Alzheimer's disease in the United States will boost the diagnostic equipment market. According to the Alzheimer's Association (2023), more than 6 million Americans are living with Alzheimer's disease. That number is projected to increase to nearly 13 million by 2050. The increasing prevalence of Alzheimer's disease in the United States will increase the demand for diagnostic devices, ultimately leading to higher overall market growth.

Benefits of all Participation:   

• Access to all scientific sessions (lectures, plenary sessions, workshops, symposia, poster presentations)
• You will receive a membership from the International Organizing Committee (IOCM certificate)
• Complete conference package with conference souvenir and final program (e-copies)
• Abstracts are published in conference souvenirs and relevant international journals
• Each abstract is given a unique DOI number assigned by Cross Ref
• Commendable speeches from the highest level of the global scientific community
• A website for over 35,000 visitors in less than 6 months
• Keynote speeches by the world's top scientists
• Cutting-edge industry representation
• Symposia and reflections Inspiring workshops
• Outstanding awards and global recognition for outstanding scientists
• Best Poster Award nominations
• Outstanding Young Researcher Award geared towards best budding young research.
• Benefits of group registration (25% off)
• Advanced research-oriented presentations
• Collaboration between science and research. Industry
• Triumph of Awards, certificates recognize your dedication to your profession to encourage new research.
• Wide variety of exhibitors to showcase new and emerging technologies.
• A platform for a global investor community to connect with stakeholders.
• An excellent platform for product presentations and international sponsoring.
• The best platform to develop new partnerships and projects. Cooperation.
• The best position to speed up your journey to any area of ​​the world.
• 89% of our conference attendees are key contacts in their universities, companies, organizations, hospitals, medical centers, and laboratories when it comes to purchasing decisions related to the field of study.